Trial Profile

Phase II Trial of Bortezomib and Bendamustine in the Treatment of Relapsed/Refractory Myeloma

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 27 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bendamustine (Primary) ; Bortezomib (Primary)
Indications Multiple myeloma
Focus Therapeutic Use

Most Recent Events

10 Jan 2018 Status changed to discontinued as PI left the institution before all data analysis was completed
31 Dec 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
16 Mar 2015 Planned End Date changed from 1 Feb 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com